GlobalData on MSN2d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoidAs Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback